Breast Cancer

FDA Follow-Up: Utilizing Olaparib in Clinical Practice for BRCA+ High Risk Early Breast Cancer

March 24, 2022

Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.

Expert Discusses Best Practices for Managing Breast Cancer–Related Toxicities

March 14, 2022

Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.